Showing papers on "Ribostamycin published in 2017"
TL;DR: Comparison of ARGs acquired from three alternate stages revealed that MLS genes and the aminoglycoside ARGs did not vary significantly in both aerobic and anaerobic sludge samples, and these results and facts will be helpful to understand the abundance and distribution of ARG from antibiotic production wastewater treatment systems.
Abstract: The occurrence of antibiotic-resistant bacteria and antibiotic resistance genes (ARGs) has been intensively investigated for wastewater treatment systems treating single class of antibiotic in recent years However, the impacts of alternately occurring antibiotics in antibiotic production wastewater on the behavior of ARGs in biological treatment systems were not well understood yet Herein, techniques including high-capacity quantitative PCR and quantitative PCR (qPCR) were used to investigate the behavior of ARGs in an anaerobic–aerobic full-scale system The system alternately treated three kinds of antibiotic production wastewater including ribostamycin, spiramycin and paromomycin, which referred to stages 1, 2 and 3 The aminoglycoside ARGs (521–793%) determined using high-capacity quantitative PCR were the most abundant species in all sludge samples of the three stages The total relative abundances of macrolide–lincosamide–streptogramin (MLS) resistance genes and aminoglycoside resistance genes measured using qPCR were significantly higher (P 005) in both aerobic and anaerobic sludge samples In aerobic sludge, one acetyltransferase gene (aacA4) and the other three nucleotidyltransferase genes (aadB, aadA and aadE) exhibited positive correlations with intI1 (r
2 = 083–094; P < 005), implying the significance of horizontal transfer in their proliferation These results and facts will be helpful to understand the abundance and distribution of ARGs from antibiotic production wastewater treatment systems
13 citations
TL;DR: The structure of RbmB from Streptomyces ribosidificus is reported, which is a pyridoxal 5′‐phosphate dependent enzyme that catalyzes two of the required steps in 2‐DOS formation by functioning on distinct substrates, and two structures represent the first detailed molecular descriptions of the active sites for those aminotransferases involved in2‐DOS production.
Abstract: Aminoglycoside antibiotics represent a classical group of antimicrobials first discovered in the 1940s. Due to their ototoxic and nephrotoxic side effects, they are typically only used against Gram negative bacteria which have become resistant to other therapeutics. One family of aminoglycosides includes such compounds as butirosin, ribostamycin, neomycin, and kanamycin, amongst others. The common theme in these antibiotics is that they are constructed around a chemically stable aminocyclitol unit referred to as 2-deoxystreptamine (2-DOS). Four enzymes are required for the in vivo production of 2-DOS. Here, we report the structure of RbmB from Streptomyces ribosidificus, which is a pyridoxal 5'-phosphate dependent enzyme that catalyzes two of the required steps in 2-DOS formation by functioning on distinct substrates. For this analysis, the structure of the external aldimine form of RbmB with 2-DOS was determined to 2.1 A resolution. In addition, the structure of a similar enzyme, BtrR from Bacillus circulans, was also determined to 2.1 A resolution in the same external aldimine form. These two structures represent the first detailed molecular descriptions of the active sites for those aminotransferases involved in 2-DOS production. Given the fact that the 2-DOS unit is widespread amongst aminoglycoside antibiotics, the data presented herein provide new molecular insight into the biosynthesis of these sugar-based drugs.
6 citations
Patent•
17 May 2017
TL;DR: In this paper, a ribostamycin sulfate injection and a preparation method for deoxygenated water is described. But the ribostamyl sulfate powder injection cannot meet terminal sterilization and the aseptic guarantee level of a powder injection is low; the stability in an expiration date is favorable.
Abstract: The invention provides a ribostamycin sulfate injection and a preparation method thereof, wherein the ribostamycin sulfate injection is prepared from the following components: 100g to 500g of ribostamycin sulfate, 1g of buffering agent, 1g of antioxidant, an appropriate amount of pH (potential of Hydrogen) regulator and 1,000ml of deoxygenated water for injection, wherein the pH of the ribostamycin sulfate injection is 4.5 to 6.5. The ribostamycin sulfate injection and the preparation method thereof, which are disclosed by the invention, have the advantages that the production process is simple and the cost is low; the problems that the ribostamycin sulfate injection cannot meet terminal sterilization and the aseptic guarantee level of a ribostamycin sulfate aseptic powder injection is low are solved; the stability in an expiration date is favorable; the bacterial contamination risk brought about as a currently clinically used powder injection needs to be anew prepared can be avoided.
4 citations
TL;DR: Phosphoramidite building blocks of ribostamycin, that may be incorporated at any position of the oligonucleotide sequence, were synthesized and studied by UV-melting profile analysis.
Abstract: Phosphoramidite building blocks of ribostamycin (3 and 4), that may be incorporated at any position of the oligonucleotide sequence, were synthesized. The building blocks, together with a previously described neomycin-modified solid support, were applied for the preparation of aminoglycoside-2′-O-methyl oligoribonucleotide fusions. The fusions were used to clamp a single strand DNA sequence (a purine-rich strand of c-Myc promoter 1) to form triple helical 2′-O-methyl RNA/DNA-hybrid constructs. The potential of the aminoglycoside moieties to stabilize the triple helical constructs were studied by UV-melting profile analysis.
3 citations
Patent•
05 Apr 2017
TL;DR: In this article, a method of preparing and purifying ribostamycin sulfate from ribostamyrin fermentation liquid is presented, which includes the following steps of: (a) adding water to dilute the rstamycin fermentation liquid, slowly adding an acidifier and conditioning the pH of the ribostamicin fermentation mixture to 5.0-6.0; (b) adding 732 cation exchange resin to the ribstamyc fermentation liquid to perform adsorption until saturation, and sucking the resin into a desorption column, back
Abstract: The invention provides a method of preparing and purifying ribostamycin sulfate from ribostamycin fermentation liquid. The method includes the following steps of: (a) adding water to dilute the ribostamycin fermentation liquid, slowly adding an acidifier and conditioning the pH of the ribostamycin fermentation liquid to 5.0-6.0; (b) adding 732 cation exchange resin to the ribostamycin fermentation liquid to perform adsorption until saturation, and sucking the resin into a desorption column, back-washing the resin with pure water to remove impurities and then back-washing the resin with deionized water until there is no chloride ions; (c) washing the cation exchange resin with diluted ammonia water and desorbing the resin with ammonia water, and collecting a desorption liquid; (d) stirring and concentrating the desorption liquid, adding a sodium hydrogen sulfite solution and a sulfuric acid solution, and adding medical activated carbon to perform desorption; and (e) filtering a carbon desorption filtrate and spray-drying the filtrate. In the method, the ribostamycin fermentation liquid is acidified, adsorbed, desorbed, concentrated, salified, carbon-desorbed and dried, thereby producing the high-purity ribostamycin sulfate. The method has simple operations and good repeatability, and can achieve industrial production.
1 citations